Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H1 2015

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H1 2015', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Secondary Progressive Multiple Sclerosis (SPMS) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Secondary Progressive Multiple Sclerosis (SPMS) Overview 7

Therapeutics Development 8

Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS)-Overview 8

Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS)-Comparative Analysis 9

Secondary Progressive Multiple Sclerosis (SPMS)-Therapeutics under Development by Companies 10

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Secondary Progressive Multiple Sclerosis (SPMS)-Products under Development by Companies 15

Secondary Progressive Multiple Sclerosis (SPMS)-Companies Involved in Therapeutics Development 16

AB Science 16

Biogen Idec Inc. 17

Daval International Ltd. 18

Genzyme Corporation 19

Glialogix, Inc. 20

Immune Response BioPharma, Inc. 21

Innate Therapeutics Limited 22

Kyorin Pharmaceutical Co., Ltd. 23

MedDay 24

Novartis AG 25

Opexa Therapeutics, Inc. 26

Secondary Progressive Multiple Sclerosis (SPMS)-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

Aimspro-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

BIIB-033-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

DC-TAB-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

GLX-1112-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

GZ-402668-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ibudilast-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

imilecleucel-t-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

interferon beta-1b-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

IR-902-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

masitinib-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

MD-1003-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

MIS-416-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

natalizumab-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

siponimod-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules for Multiple Sclerosis-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Secondary Progressive Multiple Sclerosis (SPMS)-Recent Pipeline Updates 61

Secondary Progressive Multiple Sclerosis (SPMS)-Discontinued Products 78

Secondary Progressive Multiple Sclerosis (SPMS)-Product Development Milestones 79

Featured News & Press Releases 79

Oct 07, 2014: Update on Innate's Phase 2B trial and other recent activities 79

Aug 19, 2014: Innate's Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 79

Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 80

Jun 18, 2014: Compassionate Use Programme Update 80

May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis 81

Apr 15, 2014: Innate Immunotherapeutics confirms Phase 2B trial on track and on budget 82

Mar 11, 2014: Innate Immunotherapeutics receives EU patent protection for use of MIS416 to treat or prevent radiation injury 83

Feb 03, 2014: Dr Larry Steinman, renowned multiple sclerosis specialist at Stanford University, endorses newly published MIS416 therapy validation in animal studies 83

Dec 16, 2013: Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled 84

Nov 13, 2012: Opexa Receives Clinical Trial Approval From Health Canada For New T-Cell Therapy, Tcelna 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 87

Disclaimer 87

List of Tables

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H1 2015 8

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by AB Science, H1 2015 16

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Biogen Idec Inc., H1 2015 17

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Daval International Ltd., H1 2015 18

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Genzyme Corporation, H1 2015 19

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Glialogix, Inc., H1 2015 20

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Immune Response BioPharma, Inc., H1 2015 21

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Innate Therapeutics Limited, H1 2015 22

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 23

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by MedDay, H1 2015 24

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Novartis AG, H1 2015 25

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Opexa Therapeutics, Inc., H1 2015 26

Assessment by Monotherapy Products, H1 2015 27

Number of Products by Stage and Target, H1 2015 29

Number of Products by Stage and Mechanism of Action, H1 2015 31

Number of Products by Stage and Route of Administration, H1 2015 33

Number of Products by Stage and Molecule Type, H1 2015 35

Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics-Recent Pipeline Updates, H1 2015 61

Secondary Progressive Multiple Sclerosis (SPMS)-Discontinued Products, H1 2015 78

List of Figures

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H1 2015 8

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 27

Number of Products by Top 10 Targets, H1 2015 28

Number of Products by Stage and Top 10 Targets, H1 2015 28

Number of Products by Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 32

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33

Number of Products by Top 10 Molecule Types, H1 2015 34

Number of Products by Stage and Top 10 Molecule Types, H1 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Biogen Idec Inc.

Daval International Ltd.

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Therapeutics Limited

Kyorin Pharmaceutical Co., Ltd.

MedDay

Novartis AG

Opexa Therapeutics, Inc.

Secondary Progressive Multiple Sclerosis (SPMS) Therapeutic Products under Development, Key Players in Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Overview, Secondary Progressive Multiple Sclerosis (SPMS) Pipeline, Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com